APC germline mutations in families with familial adenomatous polyposis

  • Authors:
    • Lillian Barbosa De Queiroz Rossanese
    • Fernando Augusto De Lima Marson
    • José Dirceu Ribeiro
    • Claudio Saddy Rodrigues Coy
    • Carmen Silvia Bertuzzo
  • View Affiliations

  • Published online on: August 21, 2013     https://doi.org/10.3892/or.2013.2681
  • Pages: 2081-2088
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Adenomatous polyposis coli (APC) germline mutations are responsible for the occurrence of familial adenomatous polyposis (FAP). Somatic mutations lead to malignant transformation of adenomas. In this context, considering the significance of APC germline mutations in FAP, we aimed to identify APC germline mutations. In the present study, 20 FAP patients were enrolled. The determination of APC germline mutations was performed using sequencing, and the mutations were compared with clinical markers (gender, age at diagnosis, smoking habits, TNM stage, Astler‑Coller stage, degree of differentiation of adenocarcinoma). The data were compared using the SPSS program, with the Fisher's exact test and χ2 test, considering α=0.05. According to the main results in our sample, 16 alleles with deleterious mutations (80% of the patients) were identified while 7 (35%) patients had no deleterious mutations. There was a predominance of nonsense (45% of the patients) and frameshift (20% of the patients) mutations. There was no statistical significance between the APC germline mutations identified and the clinical variables considered in our study. Only TNM stage was associated with the presence of deleterious mutations. Patients with deleterious mutations had an OR, 0.086 (IC=0.001-0.984); TNM stage I + II in comparison with III + IV, when compared with the patients with no deleterious mutations identified. In this context, as a conclusion, we demonstrated the molecular heterogeneity of APC germline mutations in FAP and the difficulty to perform molecular diagnostics in a Brazilian population, considering the admixed population analyzed.

Introduction

Colorectal cancer is common in Brazil. In the year 2012, 14,180 new cases of colon and rectum cancer were expected to occur in men and 15,960 in women. These values correspond to an estimated risk of 15 new cases per 100,000 men and 16 cases per 100,000 women (1).

Excluding non-melanoma skin tumors, colon and rectum cancer is the second most common cancer among men in Southeast Brazil (22/100,000) and third in South (18/100,000) and Midwest (14/100,000) Brazil (1). In North Brazil (4/100,000) this cancer ranks fourth; in Northeast Brazil (5/100,000), fifth. Among women, it is the second most common cancer in Southeast (23/100,000) and South Brazil (20/100,000), the third in Midwest (15/100,000) and Northeast Brazil (7/100,000), and sixth in the North (5/100,000) (1).

Familial adenomatous polyposis (FAP) is one of the most clearly defined and well understood inherited colorectal cancer syndrome. It is an autosomal dominant disorder that typically presents in the form of colorectal cancer in young adults secondary to extensive adenomatous polyposis present in the colon (2).

The adenomatous polyposis coli (APC) gene is on chromosome 5q21 and displays alternative splicing in multiple coding and noncoding regions of the DNA sequence, and the primary transcript has 15 exons. The APC gene has 8,532 base pairs corresponding to 2,844 amino acids, resulting in a 311.8-kDa protein. Exon 15 has the largest extension, making up more than three quarters of the coding region (3).

Approximately 737 APC gene mutations, including 332 germline and 402 somatic have been identified. APC germline mutations are responsible for the occurrence of FAP, and somatic mutations have been associated with malignant transformation of adenomas (4). Almost all mutations lead to truncation of the APC protein either by nonsense (30%) or by frameshift mutations (68%). The majority of mutations occur within the first half of the coding sequence. In an American study, in which 1,591 patients were studied, of the 431 pathogenic or likely pathogenic mutations, frameshift, nonsense, splice sites and large deletion or duplication mutations represented 43, 42, 9 and 6% of cases, respectively (5).

APC germline mutations are predominate at the 5′ end of the gene, while somatic mutations mainly occur in the region called the mutation cluster region (MCR) between codons 1,284 and 1,580 of the APC gene. In germline mutations, two hot spot codons have been identified; one at position 1,061 and the second at position 1,309. In somatic mutations, two hot spots seem to occur at position 1,309 and 1,450 (3).

Several studies have attempted to correlate specific APC mutations with clinical phenotypes. Mutations between codons 169 to 1,578 have been generally associated with the classic form of FAP. Mutations between codons 1,445 and 1,578 have been associated with desmoid tumors, whereas mutations between codons 279 to 1,309 have been correlated with the development of duodenal polyposis (6).

Based on the findings in the literature, the objective of the present study was to detect APC germline mutations that affect families followed up at the Oncology Clinic of the University of Campinas (Unicamp) and to compare the identified mutations with clinical variables.

Materials and methods

We recruited 20 nonrelative patients at the Oncology Service in the ‘Gastrocentro’ of the Faculty of Medical Sciences of Unicamp. The present study included families that had two or more successive generations affected by FAP (>100 polyps); no polyposis colorectal cancer was present. The project was approved by the university ethics committee (#874/2008). All patients and/or their guardians signed an informed consent form.

Clinical variables

The clinical variables analyzed in our samples included gender (male/female), age at diagnosis (≤41 or >41 years), smoking habits (passive smoking, smoker, non-smoker), TNM stage (I + II vs. III + IV), Astler-Coller stage (B1 + B2 vs. C1 + C2), degree of differentiation of adenocarcinoma (moderately differentiated, poorly differentiated, well-differentiated).

All of the variables were evaluated by medical specialists including special considerations to TNM stage (tumor, lymph node, metastasis), Astler-Coller stage and degree of differentiation of the adenocarcinoma and were evaluated taking into account previously literature (610).

DNA extraction

Genomic DNA was obtained by direct extraction from lymphocytes of peripheral blood according to standard procedures (11). DNA samples were quantified using the NanoVue® v1.7.2 spectrophotometer (GE Healthcare, Chicago, IL, USA). For all analyses performed, 50 ng/μl was used to improve the polymerase chain reaction (PCR) technique.

DNA sequencing and analysis

To identify APC mutations, DNA fragments containing the entire coding region and intron-exon boundaries of the APC gene were amplified, using PCR conditions as published by Miyoshi et al(12), Nagase et al(13) and Gómez-Fernández et al(14), with primers as listed in Table I. The precise gradients for temperature and buffers providing the optimal temperature for each fragment were determined experimentally. The PCR products indicating heterozygosity were sequenced using the Applied Biosystems (ABI) Prism BigDye Terminator v3.1 cycle sequencing kit and ABI 3500XL DNA sequencer (PE Applied Biosystems, Foster City, CA, USA), using identical conditions as previously published (1214). The DNA sequence was analyzed using GeneMapper software (Applied Biosystems) or Fragment Profiler (GE Healthcare Biosciences, Piscataway, NJ, USA).

Table I

Description of the oligonucleotides used for the analysis of the APC gene.

Table I

Description of the oligonucleotides used for the analysis of the APC gene.

Nucleotide nomenclatureSequences
APC_EX1_F 5′-AACCTTATAggTCCAAgggTAg-3′
APC_EX1_R 5′-ACCTCAAgTTTACAAgAgggAA-3′
APC_EX2_F 5′-AAATACAgAATCATgTCTTgAAgT-3′
APC_EX2_R 5′-ACACCTAAAgATgACAATTTgAg-3′
APC_EX3_F 5′-gACCCAAgTggACTTTTCAgg-3′
APC_EX3_R 5′-ACAATAAACTggAgTACACAAgg-3′
APC_EX4_F 5′-gAgAAgTTTgCAATAACAACTgATg-3′
APC_EX4_R 5′-TTATCCTgAATTTTAATggATTACCT-3′
APC_EX5_F 5′-AACCTCACTCTAACTggACCAA-3′
APC_EX5_R 5′-AACAgAgCTgTAATTCATTTTATTCC-3′
APC_EX6_F 5′-ggTAgCCATAgTATgATTATTTCT-3′
APC_EX6_R 5′-CTACCTATTTTTATACCCACAAAC-3′
APC_EX7_F 5′-AAgAAAgCCTACACCATTTTTgC-3′
APC_EX7_R 5′-gATCATTCTTAgAACCATCTTgC-3′
APC_EX8_F 5′-gACACTTCATTTggAgTACCTTAACA-3′
APC_EX8_R 5′-ggCATTAgTgACCAgggTTT-3′
APC_EX9_F 5′-AgTCgTAATTTTgTTTCTAAACTC-3′
APC_EX9_R 5′-TTTgAAACATgCACTACgAT-3′
APC_EX10_F 5′-TTgCTCTTCAAATAACAAAgCAT-3′
APC_EX10_R 5′-TCCACCAgTAATTgTCTATgTCA-3′
APC_EX11_F 5′-gATgATTgTCTTTTTCCTCTTgC-3′
APC_EX11_R 5′-CTgAgCTATCTTAAgAAATACATg-3′
APC_EX12_F 5′-TgACAAAggAAgAACAgATAgCA-3′
APC_EX12_R 5′-gCAgTgAgCTgAgATTgCAC-3′
APC_EX13_F 5′-TTTCTATTCTTACTgCTAgCATT-3′
APC_EX13_R 5′-ATACACAggTAAgAAATTAggA-3′
APC_EX14_F 5′-AgggACgggCAATAggATAg-3′
APC_EX14_R 5′-ggTCTTTTTgAgAgTATgAATTCTg-3′
APC_EX15A_F 5′-TTgTTACTgCATACACATTg-3′
APC_EX15A_R 5′-CAAATATggTgAAAggACA-3′
APC_EX15B_F 5′-CCCTAgAAgCAgAATTAg-3′
APC_EX15B_R 5′-TTCTTCTAAgTgCATTTC-3′
APC_EX15C_F 5′-CATggAAgAAgTgTCAgC-3′
APC_EX15C_R 5′-TTCTATTATgTgTTTgggTC-3′
APC_EX15D_F 5′-CACAgAATgAAAgATggg-3′
APC_EX15D_R 5′-gAAggTgTggACgTATTC-3′
APC_EX15E_F 5′-gAAACgTCATgTggATCAgC-3′
APC_EX15E_R 5′-TggCAATCgAACgACTCTC-3′
APC_EX15F_F 5′-CCTAgAACCAAATCCAgCAgAC-3′
APC_EX15F_R 5′-gTTggCATggCAgAAATAATAC-3′
APC_EX15G_F 5′-AgATgCTTgCTggACCTg-3′
APC_EX15G_R 5′-TTgCCACggAAAgTACTC-3′
APC_EX15H_F 5′-TCTTgCAgAATgCATTAATT-3′

[i] APC, adenomatous polyposis coli.

Statistical analysis

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) v.17.0 from SPSS, Inc., Chicago, IL, USA (http://www.spss.com) by Fisher’s exact test and χ2 test, considering α=0.05. To improve the data presentation, the odds ratio was calculated to variables to demonstrate the association between the clinical variables, TNM and APC germline mutation identified.

Results

In the descriptive analysis, the average age at diagnosis of the patients was 42.85 years (±6.892), and the age range was from 29 to 55 years. Of the 20 patients, 18 (90%) were Caucasian and 2 (10%) were not Caucasian; 14 (70%) were females and 6 (30%) were males. The clinical data are summarized in Table II. The frequency of cases for each stage according to the TNM system was 2 (10%), 6 (30%), 6 (30%) and 6 (30%), respectively, for stage I, II, III and IV. The frequency of cases for each stage according to the Astler-Coller system was 2 (10.5%), 5 (26.4%), 2 (10.5%) and 10 (52.6%), respectively, for stages B1, B2, C1 and C2. A smoking habit was observed in 8 patients, 2 (10%) were occasional smokers and 6 (30%) were smokers; the remaining patients (60%) were non-smokers. Two patients (10%) had well-differentiated adenocarcinoma, 15 (75%) had moderately differentiated and 3 (15%) had poorly differentiated adenocarcinoma.

Table II

The familial adenomatous polyposis patients relating to gender, race, age at diagnosis, staging (TNM and Astler-Coller), smoking habit, degree of differentiation of adenocarcinoma and APC gene genotype.

Table II

The familial adenomatous polyposis patients relating to gender, race, age at diagnosis, staging (TNM and Astler-Coller), smoking habit, degree of differentiation of adenocarcinoma and APC gene genotype.

PatientGenderRaceAge at diagnosis (years)StagingSmoking habitDegree of differentiation in adenocarcinomaGenotypeMutation deleterious/not deleteriousExtra-colonic manifestations

TNMAstler-Coller
1FC37IVC1NSMDGlu1309XDSmall intestine and duodenal polyps
2FC47IIIB2SMDSer 932 XDDuodenal polyps
3FNC31IVC2NSMDTyr935XDGastric polyps
4FC40IIC2SMDArg657Arga/c.3927_3931 delAAAGAND/DSmall intestine polyps
5FC45IVB2SMD---
6MC41IIB1SMDIle606IleaND-
7MC36IC2NSPDGln1291XDSmall intestine and duodenal polyps
8FC29IIIC2NSMDGly2502SerDGastric polyps
9MC47IIC2SMDGlu1317GlnDOsteoma jaw
10FC41IIIB2NSMDLeu629XDDuodenal polyps
11FC52IIB2NSPDAsn1037Asna/Tyr935XND/D-
12FNC40IC2NSWDThr934ThraND-
13FC44IIIC1NSMD c.3183_3186delACAADSmall intestine polyps
14MC36IVB2NSMD c.3183_3187delACAAADSmall intestine polyps
15FC55IVC2SMDArg 876XD-
16MC49IIB1PSMDLys939Lysa/Tyr951TyraND/NDGastric polyps
17FC50IINRNSWDGlu892XD-
18FC41IIIC2NSPDGly974Glya/c.3927_3931delAAAGAND/D-
19FC47IIIC2NSMDLys1454GluD-
20MC49IVC2PSMDLeu1564XDDuodenal polyps

a Neutral mutation.

{ label (or @symbol) needed for fn[@id='tfn3-or-30-05-2081'] } APC, adenomatous polyposis coli; F, female; M, male; C, Caucasian, NC, not Caucasian; NS, non-smoker; PS, possible smoker; S, smoker; MD, moderately differentiated; PD, poorly differentiated; WD, well-differentiated; D, deleterious mutations; ND, no deleterious mutations.

For the determined mutant alleles, 16 (40%) were deleterious and 7 (17.5%) were not deleterious. Associations were analyzed by correlating the TNM stage with the clinical variables, and the data are shown in Table III. The same associations were analyzed between Astler-Coller stage and the clinical variables as described in the Table IV.

Table III

Association of clinical variables of colorectal cancer according to TNM stage.

Table III

Association of clinical variables of colorectal cancer according to TNM stage.

TNM stage

VariableI and II n (%)III and IV n (%)TotalP-valueORCI (5–95%)
Gender
 Female4 (28.6)10 (71.4)140.2740.2190.014–2.242
 Male4 (66.7)2 (33.3)61-
Race
 Caucasian7 (38.9)11 (61.1)1810.6150.007–57.02
 Not Caucasian1 (50)1 (50)21-
Presence of deleterious allele
 Presence5 (31.3)11 (68.8)160.0480.086 0.001–0.984
 Absence6 (85.7)1 (14.3)71-
Degree of differentiation of adenocarcinoma
 WD2 (100)-2---
 MD4 (26.7)11 (73.3)150.1160.2050.001–1.457
 PD2 (66.7)1 (33.3)30.6883.4240.149–235.6
Age at diagnosis (years)
 ≤414 (40)6 (60)10110.119–8.417
 >414 (40)6 (60)101-
Astler-Coller stage
 B1 and B23 (42.9)4 (57.1)711.4680.142–14.66
 C1 and C24 (33.3)8 (66.7)121-
Smoking habit
 NS4 (33.3)8 (66.7)120.7770.5180.056–4.451
 S and PS4 (50)4 (50)81-

[i] TNM system: T, describes how far the main (primary) tumor has grown into the wall of the intestine and whether it has grown into nearby areas; N, describes the extent of spread to nearby (regional) lymph nodes; M, indicates whether the cancer has spread (metastasized) to other organs of the body. Astler-Coller classification: A, tumor limited to the mucosa, carcinoma in situ; B1, tumor grows through muscularis mucosa but not through muscularis propria; B2, tumor grows beyond muscularis propria; C1, stage B1 with regional lymph node metastases; C2, stage B2 with regional lymph node metastases; D, distant metastases. Statistical analysis conducted by Fisher’s exact test and χ2 test. In bold print, P-values <0.05. OR, odds ratio; CI, confidence interval; NS, non-smoker; PS, possible smoker; S, smoker; MD, moderately differentiated; PD, poorly differentiated; WD, well-differentiated.

Table IV

Association of colorectal cancer clinical variables according to Astler-Coller stage.

Table IV

Association of colorectal cancer clinical variables according to Astler-Coller stage.

Astler-Coller

VariableB1 and B2 (no.)C1 and C2 (no.)TotalP-valueORCI (5–95%)
Gender
 Female49130.6170.4650.04–5.09
 Male3361-
Race
 Caucasian710170.509--
 Not Caucasian022--
Presence of deleterious allele
 Presence510150.3760.393 0.04–3.36
 Absence4371-
Degree of differentiation of adenocarcinoma
 WD011---
 MD69150.6071.9330.12–122.2
 PD1230.8410.8410.01–19.64
Age at diagnosis (years)
 ≤4137100.6500.5540.05–5.03
 >414591-
TNM stage
 I and II34710.5540.05–5.03
 III and IV48121-
Smoking habit
 NS38110.3770.3960.04–3.67
 S and PS4481-

[i] Astler-Coller classification: A, tumor limited to mucosa, carcinoma in situ; B1, tumor grows through muscularis mucosa but not through muscularis propria; B2, tumor grows beyond muscularis propria; C1, stage B1 with regional lymph node metastases; C2, stage B2 with regional lymph node metastases; D, distant metastases. TNM system: T, describes how far the main (primary) tumor has grown into the wall of the intestine and whether it has grown into nearby areas; N, describes the extent of spread to nearby (regional) lymph nodes; M, indicates whether the cancer has spread (metastasized) to other organs of the body. Statistical analysis conducted by Fisher’s exact test and χ2 test. In bold print, P-values <0.05. OR, odds ratio; CI, confidencial interval; WD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated; NS, non-smoker; S, smoker; PS, possible smoker.

For the deleterious mutations detected, we found a prevalence of nonsense mutations, with 9 (45%) mutant alleles. In 4 (20%) patients small deletions were noted, while 3 (15%) patients had missense mutations, and 3 (15%) patients had only neutral polymorphisms and 1 (5%)patient had no mutations found in the exons. In 60% of patients, extra-colonic manifestations were present; the most common being gastric polyps, duodenal and in the small bowel (Table II).

In Figs. 1 and 2, the APC gene and all mutations identified were described in details. In the same figures, the protein structure is described, considering the principal mutation sites and their association with FAP.

Associations between the clinical variables and the identified APC germline mutations could not be calculated as the sample size was small and some of the mutations were not deleterious.

Discussion

The high molecular heterogeneity in the APC gene was consistent with other studies in FAP patients (12,18). Mutations c.3927_3931delAAAGA and pTyr935X were found in 2 patients. The c.3927_3931delAAAGA mutation occurs in exon 15 and leads to formation of a stop codon at position 1,312. It is the most frequent mutation in the APC gene. Its frequency varies from 0% in southwest Spain to 2.4% in the Australian population, 5% in the Dutch population, 7% in the Israeli population, and up to 16% in Italian FAP patients (1922). The pTyr935X mutation is a nonsense alteration of exon 15 that exchanges cytosine for adenine.

In our sample, we found a predominance of nonsense mutations (45% of the patients), followed by frameshift mutations (20% of patients). Among the 6 (30%) patients with neutral mutations, missense mutations occurred in more than 1 patient. We found the missense mutation, Gly2502Ser. According to Azzopardi et al(18), who studied 691 patients with colorectal adenomas and 969 healthy individuals (individuals investigated for cystic fibrosis), this mutation can be found in individuals with or without adenoma, leaving a doubt as to whether this mutation is deleterious.

The mutation Glu1317Gln is described in the literature as being deleterious (2327), although other studies considered it to be not deleterious. Azzopardi et al(18) found this mutation in both healthy subjects and in adenoma patients. However, we need further monitoring and analysis of these individuals with the family to gain a better understanding of this result.

For the variety of mutations, we were unable to determine a correlation between the clinical variables and the mutations detected. It is necessary to expand the sample to support such analysis. Yet, following analysis of the correlation of the presence of deleterious mutations and TNM and Astler-Coller stage, we found a positive correlation with the presence of deleterious mutations, demonstrating a more severe disease. Patients with deleterious mutations had an OR, 0.086 (IC =0.001–0.984); TNM stage I + II in comparison with III + IV, when compared with the patients with no deleterious mutations identified.

In conclusion, our study demonstrated the molecular heterogeneity of APC germline mutations in FAP and the difficulty in performing molecular diagnostics in a Brazilian population, since there were no mutations noted with a higher prevalence. Thus, molecular diagnostics requires further detailed evaluation, which, however is hampered by the presence of neutral mutations, and these mutations are still debatable in many populations of the world.

Acknowledgements

We thank FAPESP for the financial support and the Laboratório de Genética Molecular (http://www.laboratoriomultiusuario.com.br) for the possibility of the present study.

References

1 

National Cancer Institute (INCA). Estimate 2012: Cancer Incidence in Brazil. 2011, http://www.inca.gov.br/estimativa/2012/index.asp?ID=5. Accessed February 25, 2013

2 

Leblanc R: Familial adenomatous polyposis and benign intracranial tumors: a new variant of Gardner’s syndrome. Can J Neurol Sci. 27:341–346. 2000.PubMed/NCBI

3 

Dundar M, Caglayan AO, Saatci C, et al: How the 11307K adenomatous polyposis coli gene variant contributes in the assessment of risk of colorectal cancer, but not stomach cancer, in a Turkish population. Cancer Genet Cytogenet. 177:95–97. 2007. View Article : Google Scholar : PubMed/NCBI

4 

The APC mutations database - UMD. http://www.umd.be/APC/. Accessed February 25, 2013

5 

Kerr SE, Thomas CB, Thibodeau SN, et al: APC germline mutations in individuals being evaluated for familial adenomatous polyposis: a review of the Mayo Clinic experience with 1591 consecutive tests. J Mol Diagn. 15:31–43. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Zeichner SB, Raj N, Cusnir M, et al: A de novo germline APC mutation (3927del5) in a patient with familial adenomatous polyposis: case report and literature review. Clin Med Insights Oncol. 6:315–323. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Astler VB and Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 139:846–852. 1954. View Article : Google Scholar : PubMed/NCBI

8 

Way LW and Doherty GM: Cirurgia: Diagnóstico e Tratamento. 11th edition. Guanabara Koogan; Rio de Janeiro: 2004, (In Portuguese).

9 

Towsend CM, Beauchamp RD, Evers BM and Mattox KL: Sabiston, Tratado de Cirurgia: A Base Biológica da Prática Cirúrgica Moderna. Elsevier; Rio de Janeiro: 2005, (In Portuguese).

10 

World Health Organisation. Histological Typing of Intestinal Tumours. International Histological Classification of Tumours. (15)WHO; Geneva: 1976

11 

Sambrook J, Fritsch EF and Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press; New York: 1989

12 

Miyoshi Y, Ando H, Nagase H, et al: Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci USA. 89:4452–4456. 1992. View Article : Google Scholar

13 

Nagase H and Nakamura Y: Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 2:425–434. 1993. View Article : Google Scholar : PubMed/NCBI

14 

Gómez-Fernández N, Castellví-Bel S, Fernández-Rozadilla C, et al: Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations? BMC Med Genet. 10:572009.PubMed/NCBI

15 

Goss KH and Groden J: Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 18:1967–1979. 2000.PubMed/NCBI

16 

Amos-Landgraf JM, Kwong LN, Kendziorski CM, et al: A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci USA. 104:4036–4041. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Half E, Bercovich D and Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis. 4:222009. View Article : Google Scholar

18 

Azzopardi D, Dallosso AR, Eliason K, et al: Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res. 68:358–363. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Gavert N, Yaron Y, Naiman T, et al: Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. Hum Mutat. 19:6642002. View Article : Google Scholar : PubMed/NCBI

20 

Ruiz-Ponte C, Vega A, Carracedo A and Barros F: Mutation analysis of the adenomatous polyposis coli (APC) gene in northwest Spanish patients with familial adenomatous polyposis (FAP) and sporadic colorectal cancer. Hum Mutat. 18:3552001. View Article : Google Scholar : PubMed/NCBI

21 

Schnitzler M, Koorey D, Dwight T, et al: Frequency of codon 1061 and codon 1309 APC mutations in Australian familial adenomatous polyposis patients. Hum Mutat. (Suppl 1): S56–S57. 1998. View Article : Google Scholar : PubMed/NCBI

22 

Varesco L, Gismondi V, James R, et al: APC gene mutations in Italian familial polyposis coli patients. Cancer Detect Prev. 17:279–281. 1993.PubMed/NCBI

23 

Laken SJ, Petersen GM, Gruber SB, et al: Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 17:79–83. 1997. View Article : Google Scholar : PubMed/NCBI

24 

Lamlum H, Al Tassan N, Jaeger E, et al: Germline APC variants in patients with multiple colorectal adenomas, with evidence for the particular importance of E1317Q. Hum Mol Genet. 9:2215–2221. 2000. View Article : Google Scholar : PubMed/NCBI

25 

Frayling IM, Beck Ne, Ilyas M, et al: The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history. Proc Natl Acad Sci USA. 95:10722–10727. 1998. View Article : Google Scholar : PubMed/NCBI

26 

Gryfe R, Di Nicola N, Lal G, et al: Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet. 64:378–384. 1999. View Article : Google Scholar : PubMed/NCBI

27 

Hahnloser D, Petersen GM, Rabe K, et al: The APC E1317Q variant in adenomatous polyps and colorectal cancers. Cancer Epidemiol Biomarkers Prev. 12:1023–1028. 2003.PubMed/NCBI

Related Articles

Journal Cover

November 2013
Volume 30 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Rossanese LB, Marson FA, Ribeiro JD, Coy CS and Bertuzzo CS: APC germline mutations in families with familial adenomatous polyposis. Oncol Rep 30: 2081-2088, 2013.
APA
Rossanese, L.B., Marson, F.A., Ribeiro, J.D., Coy, C.S., & Bertuzzo, C.S. (2013). APC germline mutations in families with familial adenomatous polyposis. Oncology Reports, 30, 2081-2088. https://doi.org/10.3892/or.2013.2681
MLA
Rossanese, L. B., Marson, F. A., Ribeiro, J. D., Coy, C. S., Bertuzzo, C. S."APC germline mutations in families with familial adenomatous polyposis". Oncology Reports 30.5 (2013): 2081-2088.
Chicago
Rossanese, L. B., Marson, F. A., Ribeiro, J. D., Coy, C. S., Bertuzzo, C. S."APC germline mutations in families with familial adenomatous polyposis". Oncology Reports 30, no. 5 (2013): 2081-2088. https://doi.org/10.3892/or.2013.2681